Literature DB >> 17324932

Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase.

Lan Xu1, Youhoon Chong, Inkyu Hwang, Anthony D'Onofrio, Kristen Amore, G Peter Beardsley, Chenglong Li, Arthur J Olson, Dale L Boger, Ian A Wilson.   

Abstract

The inosine monophosphate cyclohydrolase (IMPCH) component (residues 1-199) of the bifunctional enzyme aminoimidazole-4-carboxamide ribonucleotide transformylase (AICAR Tfase, residues 200-593)/IMPCH (ATIC) catalyzes the final step in the de novo purine biosynthesis pathway that produces IMP. As a potential target for antineoplastic intervention, we designed IMPCH inhibitors, 1,5-dihydroimidazo[4,5-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxide (heterocycle, 1), the corresponding nucleoside (2), and the nucleoside monophosphate (nucleotide) (3), as mimics of the tetrahedral intermediate in the cyclization reaction. All compounds are competitive inhibitors against IMPCH (K(i) values = 0.13-0.23 microm) with the simple heterocycle 1 exhibiting the most potent inhibition (K(i) = 0.13 microm). Crystal structures of bifunctional ATIC in complex with nucleoside 2 and nucleotide 3 revealed IMPCH binding modes similar to that of the IMPCH feedback inhibitor, xanthosine 5'-monophosphate. Surprisingly, the simpler heterocycle 1 had a completely different IMPCH binding mode and was relocated to the phosphate binding pocket that was identified from previous xanthosine 5'-monophosphate structures. The aromatic imidazole ring interacts with a helix dipole, similar to the interaction with the phosphate moiety of 3. The crystal structures not only revealed the mechanism of inhibition of these compounds, but they now serve as a platform for future inhibitor improvements. Importantly, the nucleoside-complexed structure supports the notion that inhibitors lacking a negatively charged phosphate can still inhibit IMPCH activity with comparable potency to phosphate-containing inhibitors. Provocatively, the nucleotide inhibitor 3 also binds to the AICAR Tfase domain of ATIC, which now provides a lead compound for the design of inhibitors that simultaneously target both active sites of this bifunctional enzyme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17324932     DOI: 10.1074/jbc.M607293200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Expression, purification, crystallization and preliminary X-ray diffraction crystallographic study of PurH from Escherichia coli.

Authors:  Xiaoting Qiu; Ye Yuan; Yongxiang Gao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-11-26

2.  Structural analyses of a purine biosynthetic enzyme from Mycobacterium tuberculosis reveal a novel bound nucleotide.

Authors:  Jérôme Le Nours; Esther M M Bulloch; Zhening Zhang; David R Greenwood; Martin J Middleditch; James M J Dickson; Edward N Baker
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

3.  Biological and structural evaluation of 10R- and 10S-methylthio-DDACTHF reveals a new role for sulfur in inhibition of glycinamide ribonucleotide transformylase.

Authors:  Stephen Connelly; Jessica K DeMartino; Dale L Boger; Ian A Wilson
Journal:  Biochemistry       Date:  2013-07-19       Impact factor: 3.162

Review 4.  Structural biology of the purine biosynthetic pathway.

Authors:  Y Zhang; M Morar; S E Ealick
Journal:  Cell Mol Life Sci       Date:  2008-11       Impact factor: 9.261

5.  Different Ways of Doing the Same: Variations in the Two Last Steps of the Purine Biosynthetic Pathway in Prokaryotes.

Authors:  Dennifier Costa Brandão Cruz; Lenon Lima Santana; Alexandre Siqueira Guedes; Jorge Teodoro de Souza; Phellippe Arthur Santos Marbach
Journal:  Genome Biol Evol       Date:  2019-04-01       Impact factor: 3.416

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.